Residual Exacerbations With Mepolizumab
Recruiting now NCT04578171
Run by Laval University · for 18 to 90 · All sexes
What this study is about
This will be a two-year prospective study to characterize the nature of the remaining asthma exacerbations in patients treated with mepolizumab. Participants will be assessed every six months from pre- until two years of treatment in addition to whenever they experience an exacerbation of asthma during the study period. During these visits, various clinical, physiological and inflammatory outcomes will be assessed.
Who can join (things the study team will check)
✅ You may be able to join if…
- With a proven diagnosis of severe asthma as defined by the Canadian Thoracic Society
- Eligible for mepolizumab treatment
- Able and willing to sign the informed consent form
🚫 You may not be able to join if…
- Any respiratory disease apart from asthma
- Confounding comorbidities sur as eosinophilic granulomatosis with polyangiitis (EGPA) or hypereosinophilic syndrome
Where this trial is running
- Institut universitaire de cardiologie et de pneumologie de Québec, Québec, Quebec, Canada
Who to contact
Marie-Eve Boulay, MSc · 4186568711 · marie-eve.boulay@criucpq.ulaval.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT04578171.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.